ArticleJournal of advanced research2026
An injectable nano-hydroxyapatite-incorporated hydrogel with sustained release of Notoginsenoside R1 enhances bone regeneration by promoting angiogenesis through Notch1/Akt signaling.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Innovative Hydroxyapatite-Hydrogel Composites for Cartilage Regeneration.Gels (Basel, Switzerland) · 2026Review
- Cerium-doped prussian blue nanozymes for bone regeneration and osteoprotection by Lhx2 in sutural distraction osteogenesis through multi-omics analysis.Journal of nanobiotechnology · 2026Article
- Hydroxyapatite-based bone repair biomaterials based on clinical heterogeneity: modification strategies, performance regulation, and personalized repair pathways.Frontiers in bioengineering and biotechnology · 2026Review
- GelMA-Based Nanocomposites for Bone Defect Regeneration: Design, Performance, and Clinical Translation Potential.International journal of nanomedicine · 2026Review
- Natural bioactive products in the regulation of bone metabolism and regeneration.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNotoginsenoside R1 (NGR1), a bioactive compound, exhibits significant pro-angiogenic potential, making it a promising candidate for treating various diseases. Since angiogenesis and osteogenesis are synergistically coupled processes, NGR1's capacity to stimulate blood vessel formation may critically promote bone regeneration. However, the underlying molecular mechanisms through which NGR1 promotes angiogenesis in bone repair remain to be fully elucidated.
objectivesTo investigate the potential mechanism by which NGR1 promotes angiogenesis and to validate the therapeutic effect of NGR1-loaded biomaterials on bone defect regeneration.
methodsHuman umbilical vein endothelial cells (HUVECs) were cultured in complete medium containing the screened concentration of NGR1 to investigate its pro-angiogenic phenotype and potential mechanism in vitro. Subsequently, an injectable nano-hydroxyapatite-incorporated GelMA hydrogel was synthesized as an active drug-delivery delivery system for NGR1. The therapeutic effect of this fabricated NGR1-loaded biomaterial on bone defect regeneration was further evaluated in a rat cranial bone defect model. The key molecules in relevant signaling pathways was analyzed by immunohistochemistry.
resultsIn vitro experiments demonstrated that NGR1 exhibits good biocompatibility and angiogenic capacity, as it promoted cell proliferation, enhanced cell migration, upregulated the angiogenic-related gene expression, and increased the protein expression of VEGF and VEGFR-2. Furthermore, the implantation of the injectable nano-hydroxyapatite-incorporated GelMA hydrogel loaded with NGR1 significantly enhanced bone defect regeneration in a rat cranial bone defect model compared to hydrogel-only group. Additionally, NGR1 supplementation markedly upregulated CD31 expression during bone formation, suggesting its role in coupling of angiogenesis and osteogenesis. Mechanistically, both in vivo and in vitro experiments indicated that NGR1 likely promote angiogenesis via activating Notch1/Akt singling pathway during bone regeneration.
conclusionsThese findings indicate that NGR1 promotes angiogenesis through Notch1/Akt signaling activation during bone regeneration, which might offer potential therapeutic targets for bone-related diseases. Moreover, the application of NGR1-loaded biomaterials could represent a promising strategy to enhance bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.